menu
    • menu

    Find Lifitegrast manufacturers, exporters & distributors on PharmaCompass

    Interquim Lifitegrast

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Gentec SA Lifitegrast

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    26

    API Suppliers

    API Suppliers

    12

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    2

    EU WC

    EU WC

    4

    KDMF

    KDMF

    14

    NDC API

    NDC API

    0

    VMF

    NDC API

    21

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 0

    MARKET PLACE

    10

    API

    1

    FDF

    14INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    7

    FDF Dossiers

    FDF Dossiers

    5

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    1

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    1

    Listed Dossiers

    Listed Dossiers

    4DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    16

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    3

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    38

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    333,902,961

    Annual Reports

    1,523

    Finished Drug Prices

    NA

    3 RELATED EXCIPIENT COMPANIES

    3EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 1025967-78-5, Xiidra, Sar 1118, Sar-1118, Shp606, Shp-606
    Molecular Formula
    C29H24Cl2N2O7S
    Molecular Weight
    615.5  g/mol
    InChI Key
    JFOZKMSJYSPYLN-QHCPKHFHSA-N
    FDA UNII
    038E5L962W
    Lifitegrast
    Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting.
    Lifitegrast is a Lymphocyte Function-Associated Antigen-1 Antagonist. The mechanism of action of lifitegrast is as a Lymphocyte Function-Associated Antigen-1 Antagonist.
    1 2D Structure

    Lifitegrast

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid
    2.1.2 InChI
    InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
    2.1.3 InChI Key
    JFOZKMSJYSPYLN-QHCPKHFHSA-N
    2.1.4 Canonical SMILES
    CS(=O)(=O)C1=CC=CC(=C1)CC(C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl
    2.1.5 Isomeric SMILES
    CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    038E5L962W
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (2s)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- Yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic Acid

    2. L-phenylalanine, N-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)-

    3. Lifitegrast Ophthalmic Solution

    4. Sar 1118

    5. Sar-1118

    6. Shp-606

    7. Shp606

    8. Xiidra

    2.3.2 Depositor-Supplied Synonyms

    1. 1025967-78-5

    2. Xiidra

    3. Sar 1118

    4. Sar-1118

    5. Shp606

    6. Shp-606

    7. (s)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic Acid

    8. Chembl2048028

    9. 038e5l962w

    10. (2s)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6- Yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic Acid

    11. L-phenylalanine, N-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)-

    12. L-phenylalanine, N-[[2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-

    13. Lifitegrast [usan:inn]

    14. Unii-038e5l962w

    15. Sar1118

    16. Xiidra (tn)

    17. Lifitegrast [mi]

    18. Lifitegrast [inn]

    19. Lifitegrast (usan/inn)

    20. Lifitegrast [usan]

    21. Lifitegrast; Sar 1118

    22. Lifitegrast [who-dd]

    23. Lifitegrast Ophthalmic Solution

    24. Gtpl7533

    25. Schembl2632068

    26. Amy4450

    27. Dtxsid60145345

    28. Lifitegrast [orange Book]

    29. Chebi:133023

    30. Ex-a2582

    31. Bdbm50386331

    32. Mfcd28502439

    33. S3714

    34. Zinc84668739

    35. Ccg-270245

    36. Cs-6264

    37. Db11611

    38. Compound 1g [pmid: 24900456]

    39. Ac-32534

    40. Ds-20052

    41. Hy-19344

    42. D10374

    43. A900838

    44. Q23044263

    45. (2s)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro3,4-dihydro-1h-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic Acid

    46. N-[[2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-l-phenylalanine

    47. N-[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carbonyl]-3-(methanesulfonyl)-l-phenylalanine

    2.4 Create Date
    2006-12-18
    3 Chemical and Physical Properties
    Molecular Weight 615.5 g/mol
    Molecular Formula C29H24Cl2N2O7S
    XLogP34.7
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count7
    Exact Mass614.0681277 g/mol
    Monoisotopic Mass614.0681277 g/mol
    Topological Polar Surface Area142 Ų
    Heavy Atom Count41
    Formal Charge0
    Complexity1100
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    For the treatment of signs and symptoms of keratoconjunctivitis sicca (dry eye syndrome).

    FDA Label

    Treatment of dry eye disease

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Lifitegrast addresses both the symptoms and the resulting ocular surface damage by interfering with ocular inflammatory cycle. Lifitegrast is a lymphocyte functionassociated antigen-1 antagonist through direct competitive antagonism and sequentially inhibits the T-cell recruitment, activation, and proinflammatory cytokine release associated with dry eye syndrome.

    5.2 MeSH Pharmacological Classification

    Ophthalmic Solutions

    Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. (See all compounds classified as Ophthalmic Solutions.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    LIFITEGRAST
    5.3.2 FDA UNII
    038E5L962W
    5.3.3 Pharmacological Classes
    Lymphocyte Function-Associated Antigen-1 Antagonists [MoA]; Lymphocyte Function-Associated Antigen-1 Antagonist [EPC]
    5.4 ATC Code

    S - Sensory organs

    S01 - Ophthalmologicals

    S01X - Other ophthalmologicals

    S01XA - Other ophthalmologicals

    S01XA25 - Lifitegrast

    5.5 Absorption, Distribution and Excretion

    Absorption

    The mean peak plasma concentration (Cmax) of 1.70ng/mL was reached within 15 minutes of application. Quantifiable trough plasma concentrations ranged from 0.55 ng/mL to 3.74 ng/mL. Observations show limited systemic exposure that produces significant clinical outcomes.

    Route of Elimination

    Not possible to perform mass balance study to determine the main route of elimination.

    Clearance

    Not possible to calculate clearance rate based on plasma concentrations of lifitegrast, but reported to be relatively fast in rat I.V. pharmacokinetics study. It is predicted that lifitegrast is cleared via nasal and subsequently gastrointestinal tract.

    5.6 Metabolism/Metabolites

    Based on the findings of an in vitro metabolism study using fresh human hepatocytes, lifitegrast does not appear to undergo significant metabolism.

    5.7 Biological Half-Life

    Not possible to calculate plasma elimination half-life based on plasma concentrations of lifitegrast, but reported to be relatively short in rat I.V. pharmacokinetics study.

    5.8 Mechanism of Action

    Lifitegrast binds to the integrin lymphocyte function-associated antigen-1 (LFA-1), a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in dry eye disease. LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell proliferation/activation and migration to target tissues. In vitro studies demonstrated that lifitegrast may inhibit T-cell adhesion to ICAM-1 in a human T-cell line and may inhibit secretion of inflammatory cytokines, inflammatory mediators, chemokines, TNF-, and IL-1 in human peripheral blood mononuclear cells.

    API SUPPLIERS

    read-more
    read-more

    01

    Interquim SA

    Spain

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 35652

    Submission : 2022-07-18

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 64552-4088

    Start Marketing Date : 2016-11-07

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    Interquim

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Gentec Pharmaceutical Group

    Spain

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Booth #11.1C90
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothGentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Gentec Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Metrochem API Private Limited

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Metrochem

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Dr. Reddy's Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2019-10-29

    Pay. Date : 2019-09-27

    DMF Number : 33681

    Submission : 2019-03-29

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    HRV Global Life Sciences

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothHRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF AU arrow-down
    ✖
    Available Reg Filing : AU
    AUDIT
    HRV Global Life Sciences

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    ScinoPharm Taiwan, Ltd

    Taiwan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    ScinoPharm Taiwan, Ltd

    Taiwan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2024-07-01

    Pay. Date : 2024-06-06

    DMF Number : 35421

    Submission : 2020-12-28

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 65129-1428

    Start Marketing Date : 2020-10-01

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Fuan Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Fuan Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 38179

    Submission : 2023-04-20

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Glenmark Life Sciences

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Glenmark Life Sciences

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2019-04-23

    Pay. Date : 2019-03-28

    DMF Number : 33711

    Submission : 2019-03-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2023-12-28

    Valid Till : 2026-12-28

    Written Confirmation Number : WC-0310

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 66039-948

    Start Marketing Date : 2019-08-29

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF arrow-down
    ✖

    Registrant Name : M-Peak Korea Co., Ltd.

    Registration Date : 2021-08-11

    Registration Number : Number 812-15-ND

    Manufacturer Name : Glenmark Life Sciences Ltd

    Manufacturer Address : Plot No.Z-103/ I, DAHEJ SEZ Phase II, City : Dahej, District : Bharuch, Gujarat State, India

     VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Viwit Pharmaceuticals Limited

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Viwit Pharmaceuticals Limited

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40172

    Submission : 2024-08-09

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Sun Pharmaceutical Industries Limi...

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Sun Pharmaceutical Industries Limi...

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2020-04-28

    Pay. Date : 2020-03-23

    DMF Number : 34700

    Submission : 2020-04-10

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-more

    01

    Interquim Sa

    Spain
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 35652

    Submission : 2022-07-18

    Status : Active

    Type : II

    Interquim

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Dr Reddys Laboratories Ltd

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : Complete

    Rev. Date : 2019-10-29

    Pay. Date : 2019-09-27

    DMF Number : 33681

    Submission : 2019-03-29

    Status : Active

    Type : II

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Pharma, Lab & Chemical Expo
    Not Confirmed

    03

    Apitoria Pharma Private Ltd

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2020-03-09

    Pay. Date : 2020-02-13

    DMF Number : 34576

    Submission : 2020-02-15

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Pharma, Lab & Chemical Expo
    Not Confirmed

    04

    Guang'an Kingday Pharma And Chem Co ...

    China
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 38179

    Submission : 2023-04-20

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Pharma, Lab & Chemical Expo
    Not Confirmed

    05

    Glenmark Life Sciences Ltd

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2019-04-23

    Pay. Date : 2019-03-28

    DMF Number : 33711

    Submission : 2019-03-30

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Micro Labs Ltd

    India

    USDMF

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    06

    Micro Labs Ltd

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2020-06-02

    Pay. Date : 2020-05-08

    DMF Number : 34735

    Submission : 2020-04-29

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Pharma, Lab & Chemical Expo
    Not Confirmed

    07

    Msn Life Sciences Private Ltd

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 34280

    Submission : 2019-11-02

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Olon Spa

    Italy

    USDMF

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    08

    Olon Spa

    Italy
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 37215

    Submission : 2022-09-26

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Olon Spa

    Italy

    USDMF

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    09

    Olon Spa

    Italy
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2020-04-14

    Pay. Date : 2020-01-27

    DMF Number : 34551

    Submission : 2020-02-04

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Scinopharm Taiwan Ltd

    Taiwan

    USDMF

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    10

    Scinopharm Taiwan Ltd

    Taiwan
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2024-07-01

    Pay. Date : 2024-06-06

    DMF Number : 35421

    Submission : 2020-12-28

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis Completes Divestment of ‘Front of Eye’ Ophthalmology Assets

    Details:

    Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ocular surface pain.


    Lead Product(s): Lifitegrast

    Therapeutic Area: Ophthalmology Brand Name: Xiidra

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Bausch & Lomb Incorporated

    Deal Size: $2,500.0 million Upfront Cash: $1,750.0 million

    Deal Type: Divestment September 29, 2023

    blank

    01

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    AES 2024
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lifitegrast

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Bausch & Lomb Incorporated

    Deal Size : $2,500.0 million

    Deal Type : Divestment

    DEALS_DEV arrow-down

    Novartis Completes Divestment of ‘Front of Eye’ Ophthalmology Assets

    Details : Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ...

    Brand Name : Xiidra

    Molecule Type : Small molecule

    Upfront Cash : $1,750.0 million

    September 29, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

    Details:

    The financing will fund the acquisition Xiidra (lifitegrast ophthalmic solution), a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.


    Lead Product(s): Lifitegrast

    Therapeutic Area: Ophthalmology Brand Name: Xiidra

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Undisclosed

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Financing September 11, 2023

    blank

    02

    Bausch & Lomb Incorporated

    Canada
    arrow
    AES 2024
    Not Confirmed

    Bausch & Lomb Incorporated

    Canada
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lifitegrast

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Undisclosed

    Deal Type : Financing

    DEALS_DEV arrow-down

    Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

    Details : The financing will fund the acquisition Xiidra (lifitegrast ophthalmic solution), a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalm...

    Brand Name : Xiidra

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    September 11, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis Signs Agreement to Divest Front of Eye Ophthalmology Assets in Line with Focused Strategy

    Details:

    Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ocular surface pain.


    Lead Product(s): Lifitegrast

    Therapeutic Area: Ophthalmology Brand Name: Xiidra

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Bausch & Lomb Incorporated

    Deal Size: $2,500.0 million Upfront Cash: $1,750.0 million

    Deal Type: Divestment June 30, 2023

    blank

    03

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    AES 2024
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lifitegrast

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Bausch & Lomb Incorporated

    Deal Size : $2,500.0 million

    Deal Type : Divestment

    DEALS_DEV arrow-down

    Novartis Signs Agreement to Divest Front of Eye Ophthalmology Assets in Line with Focused Strategy

    Details : Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ...

    Brand Name : Xiidra

    Molecule Type : Small molecule

    Upfront Cash : $1,750.0 million

    June 30, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis Acquires Kedalion Therapeutics and Its Innovative Ocular Delivery Platform that Could Transform Patient Experience

    Details:

    Novartis intends to develop the AcuStream technology for potential use with its existing and future front-of-eye therapies, which could include Xiidra® (lifitegrast ophthalmic solution) 5%, a first-in-class prescription LFA 1 antagonist for the treatment of dry eye disease.


    Lead Product(s): Lifitegrast

    Therapeutic Area: Ophthalmology Brand Name: Xiidra

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Novartis Pharmaceuticals Corporation

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition June 30, 2022

    blank

    04

    Kedalion Therapeutics

    U.S.A
    arrow
    AES 2024
    Not Confirmed

    Kedalion Therapeutics

    U.S.A
    arrow
    AES 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lifitegrast

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Novartis Acquires Kedalion Therapeutics and Its Innovative Ocular Delivery Platform that Could Tra...

    Details : Novartis intends to develop the AcuStream technology for potential use with its existing and future front-of-eye therapies, which could include Xiidra® (lifitegrast ophthalmic solution) 5%, a first-in-class prescription LFA 1 antagonist for the treatmen...

    Brand Name : Xiidra

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    June 30, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Pharmathen SA

    Greece
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Contact Supplier Contact Supplier
    Flag Greece
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Greece

    Lifitegrast

    Brand Name :

    Dosage Form : Ophthalmic Solution

    Dosage Strength : 50MG/ML

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Greece

    Pharmathen

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Ajanta Pharma Limited

    India
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Ajanta Pharma Limited

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    LIFITEGRAST

    Brand Name : LIFITEGRAST

    Dosage Form : SOLUTION/DROPS;OPHTHALMIC

    Dosage Strength : 5%

    Packaging :

    Approval Date : 2024-10-03

    Application Number : 215058

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Aurobindo Pharma Limited

    India
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Aurobindo Pharma Limited

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : DISCN

    Registration Country : USA

    LIFITEGRAST

    Brand Name : LIFITEGRAST

    Dosage Form : SOLUTION/DROPS;OPHTHALMIC

    Dosage Strength : 5%

    Packaging :

    Approval Date : 2023-11-07

    Application Number : 215063

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Bausch & Lomb Incorporated

    Canada
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Bausch & Lomb Incorporated

    Canada
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Canada
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    LIFITEGRAST

    Brand Name : XIIDRA

    Dosage Form : SOLUTION/DROPS;OPHTHALMIC

    Dosage Strength : 5%

    Packaging :

    Approval Date : 2016-07-11

    Application Number : 208073

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Micro Labs Limited

    India
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Micro Labs Limited

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : DISCN

    Registration Country : USA

    LIFITEGRAST

    Brand Name : LIFITEGRAST

    Dosage Form : SOLUTION/DROPS;OPHTHALMIC

    Dosage Strength : 5%

    Packaging :

    Approval Date : 2023-08-04

    Application Number : 215081

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Novartis Pharmaceuticals Corporatio...

    Switzerland
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    LIFITEGRAST

    Brand Name : XIIDRA

    Dosage Form : SOLUTION

    Dosage Strength : 5%/W/V

    Packaging :

    Approval Date :

    Application Number : 2471027

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Sun Pharmaceutical Industries Limit...

    India
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Sun Pharmaceutical Industries Limit...

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : USA

    LIFITEGRAST

    Brand Name : LIFITEGRAST

    Dosage Form : SOLUTION/DROPS;OPHTHALMIC

    Dosage Strength : 5%

    Packaging :

    Approval Date :

    Application Number : 215126

    Regulatory Info :

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    01

    INGENUS PHARMS LLC

    India
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    INGENUS PHARMS LLC

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : No

    TE Code : AB

    LIFITEGRAST

    Brand Name : LIFITEGRAST

    Dosage Form : SOLUTION/DROPS;OPHTHALMIC

    Dosage Strength : 5%

    Approval Date : 2024-10-03

    Application Number : 215058

    RX/OTC/DISCN : RX

    RLD : No

    TE Code : AB

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    EUGIA PHARMA

    India
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    EUGIA PHARMA

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : No

    TE Code :

    LIFITEGRAST

    Brand Name : LIFITEGRAST

    Dosage Form : SOLUTION/DROPS;OPHTHALMIC

    Dosage Strength : 5%

    Approval Date : 2023-11-07

    Application Number : 215063

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    BAUSCH AND LOMB INC

    Canada
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    BAUSCH AND LOMB INC

    Canada
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Canada
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : Yes

    TE Code : AB

    LIFITEGRAST

    Brand Name : XIIDRA

    Dosage Form : SOLUTION/DROPS;OPHTHALMIC

    Dosage Strength : 5%

    Approval Date : 2016-07-11

    Application Number : 208073

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code : AB

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    MICRO LABS

    India
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    MICRO LABS

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : No

    TE Code :

    LIFITEGRAST

    Brand Name : LIFITEGRAST

    Dosage Form : SOLUTION/DROPS;OPHTHALMIC

    Dosage Strength : 5%

    Approval Date : 2023-08-04

    Application Number : 215081

    RX/OTC/DISCN : DISCN

    RLD : No

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    SUN PHARM INDS LTD

    India
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    SUN PHARM INDS LTD

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD :

    TE Code :

    LIFITEGRAST

    Brand Name : LIFITEGRAST

    Dosage Form : SOLUTION/DROPS;OPHTHALMIC

    Dosage Strength : 5%

    Approval Date :

    Application Number : 215126

    RX/OTC/DISCN :

    RLD :

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Canada

    read-more
    read-more

    01

    NOVARTIS PHARMACEUTICALS CANADA INC

    Switzerland
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    NOVARTIS PHARMACEUTICALS CANADA INC

    Switzerland
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Canada

    LIFITEGRAST

    Brand Name : XIIDRA

    Dosage Form : SOLUTION

    Dosage Strength : 5%/W/V

    Packaging :

    Approval Date :

    Application Number : 2471027

    Regulatory Info : Prescription

    Registration Country : Canada

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Dossiers

    read-more
    read-more

    01

    Pharmathen SA

    Greece
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Contact Supplier Contact Supplier
    Flag Greece
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Greece

    Lifitegrast

    Brand Name :

    Dosage Form : Ophthalmic Solution

    Dosage Strength : 50MG/ML

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Greece

    Pharmathen

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    01

    Pharmathen SA

    Greece
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

    Contact Supplier Contact Supplier
    Flag Greece
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info :

    Lifitegrast

    Dosage : Ophthalmic Solution

    Dosage Strength : 50MG/ML

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : Greece

    Pharmathen

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    APIs

    read-more
    read-more
    india-flag.png
    Lifitegrast API needed in India [ENA19887]
    A company that focuses on development of comprehensive solutions in oral and parenteral drug delivery systems, analytical sciences, and pre-formulation studies is looking for suppliers of Lifitegrast API. The required quantity is 1 kg - 3 kg for development and 50 kg for commercial purposes. The suppliers must support this enquiry with USDMF & CoA.
    05 Jul 2024

    Reply

    05 Jul 2024

    Reply text-arrow

    Reply Comment (3)

    05 Jul 2024

    india-flag.png
    Lifitegrast API needed in India [ENA18792]
    A CDMO that focuses on the research, development & manufacturing of tablets, capsules, creams, gels and sprays is looking for suppliers of Lifitegrast (2 kg - 5 kg) API for development purposes. The suppliers must support this enquiry with CoA.
    20 Dec 2023

    Reply

    20 Dec 2023

    Reply text-arrow

    Reply Comment (5)

    20 Dec 2023

    india-flag.png
    Lifitegrast (100 g) API needed in India [ENA14089]
    A company that focuses in discovery, development, manufacturing and marketing a broad range of healthcare products is looking for suppliers of Lifitegrast (100 g) API for development purpose. The suppliers must support this enquiry with CoA.
    24 Jun 2022

    Reply

    24 Jun 2022

    Reply text-arrow

    Reply Comment (4)

    24 Jun 2022

    india-flag.png
    Various APIs needed in India [ENA10641]
    A company specializing in analytical testing of a range of drug delivery systems is looking for Various APIs for development purposes. The required quantity is 50 g for each. The suppliers must support this enquiry with USDMF. The final market is the US. 1. USP Grade Brimonidine Tartrate API 2. Travoprost API 3. Timolol Maleate API 4. Budesonide (Sterile) API 5. Varenicline Tartrate API 6. Formoterol Fumarate API 7. Arformoterol Tartrate API 8. USP Grade Brinzolamide (Micronized) API 9. Loteprednol Etabonate API 10. Lifitegrast API 11. Naloxone Hydrochloride API
    15 Jun 2021

    Reply

    15 Jun 2021

    Reply text-arrow

    Reply Comment (7)

    15 Jun 2021

    China.png
    Lifitegrast API needed in China [ENA05966]
    A company focusing on research and development of generic drugs is looking for suppliers of Lifitegrast API. The supplier must support this enquiry with CoA.
    06 Dec 2019

    Reply

    06 Dec 2019

    Reply text-arrow

    Reply Comment (4)

    06 Dec 2019

    korearepublicofnew.png
    Perampanel, Metoclopramide & other APIs needed in Korea [ENA05440]
    Rihu Healthcare, a leading value-added and multifunctional trader and distributor of pharmaceutical products, chemicals and functional health industries in Korea is looking for suppliers of below mentioned APIs. The supplier must support this enquiry with CoA and GMP. Interested suppliers can contact them via Email: justin.lim@rihuhealthcare.com. 1. Perampanel 2. Metoclopramide base 3. Brivaracetam 4. Lifitegrast 5. Cimetidine 6. Choline Chloride 7. Isolated Soy protein 8. Sodium Caseinate 9. Soybean Phospholipids 10. Calcium caseinate 11. Corn Oil
    15 Oct 2019

    Reply

    15 Oct 2019

    Reply text-arrow

    Reply Comment (5)

    15 Oct 2019

    Bangladesh.png
    Lifitegrast (2-5 kg) API needed in Bangladesh [ENA04760]
    One of the fastest growing indenting company based in Bangladesh providing quality services is looking for suppliers of Lifitegrast (2-5 kg) API. The supplier must support this enquiry with the following documentations: 1. CoA 2. MoA 3. MSDS 4. GMP 5. DMF.
    30 Jul 2019

    Reply

    30 Jul 2019

    Reply text-arrow

    Reply Comment (6)

    30 Jul 2019

    Iran.png
    USP/EP grade Miglustat and Lifitegrast APIs needed in Iran [ENA04551]
    A generic developing company mainly dealing in injectables, solid dosage forms and sterile drops is looking for suppliers of USP/EP grade Miglustat and Lifitegrast APIs.
    04 Jul 2019

    Reply

    04 Jul 2019

    Reply text-arrow

    Reply Comment (10)

    04 Jul 2019

    Bangladesh.png
    Lifitegrast (Sterile) API needed in Bangladesh [ENA02291]
    ASN corporation- a prominent and leading Trading Company in Bangladesh, engaged in sales and marketing of Pharmaceutical Packing Materials & Raw Materials (API’s), Intermediates, Excipients, Vitamins, Flavors, Coating materials etc is looking for suppliers of Lifitegrast (Sterile) API. Interested suppliers must support this enquiry with Certificate of Analysis (COA), a valid GMP Certificate.
    13 Oct 2018

    Reply

    13 Oct 2018

    Reply text-arrow

    Reply Comment (1)

    13 Oct 2018

    Market Place
    Enquiry// Lifitegrast API needed in Colombia [ENA00873]
    A Colombia based manufacturing and commercializing company of specialized pharmaceutical forms, located in the city of Barranquilla is searching for suppliers of Lifitegrast API for domestic consumption.
    01 May 2018

    Reply

    01 May 2018

    Reply text-arrow

    Reply Comment (1)

    01 May 2018

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search